Self-monitoring and treatment of chronic non-communicable diseases in the context of the COVID-19 pandemic. Consensus of experts of the National society of evidence-based pharmacotherapy and the Russian society of the prevention of non-communicable diseases

In the current epidemic of a new coronavirus infection, COVID-19 treatment of patients with chronic non-communicable diseases (NCDS) and cardiovascular diseases (CVD), in particular, requires close attention of doctors. The main objectives of such patients’ management tactics are to ensure that patients comply with self-isolation measures that prevent infection, motivate patients to follow all medical recommendations. Special attention should be paid to comply with recommended treatment of CVD. In the case of an infectious disease, it is necessary to assess the prescribed therapy for interaction with medications already taken by the patient. However, the tactics for COVID-19 therapy, including in patients with NCDS, may change over time, since there are currently no drugs with proven effectiveness for the treatment of a new coronavirus infection.

1. Prevention, diagnosis and treatment of a new coronavirus infection. The provisional guidelines. Version 5 from 02.04.2020 of the Ministry of Health of the Russian Federation. 112 p. (In Russ.) Available at https://static-1.rosminzdrav.ru/system/attachments/attaches/000/049/951/original/09042020_%D0%9C%D0%A0_COVID19_v5.pdf.

2. Russian statistical yearbook. Moscow: Rosstat; 2019. 708 р. (In Russ.) Available at https://www.gks.ru/storage/mediabank/Ejegodnik_2019.pdf.

3. Tolpygina SN, Martsevich SYu, Kontsevaya AV, Drapkina OM. Responsible self-care — the fundamental principles and place in the modern Russian healthcare system. Rational Pharmacotherapy in Cardiology. 2018;14(1):101-10. (In Russ.) doi:10.20996/1819-6446-2018-14-1-101-110.

4. Kuster GM, Pfister O, Burkard T. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020. pii: ehaa235. doi:10.1093/eurheartj/ehaa235. [Epub ahead of print].

5. Drug therapy of acute respiratory viral infections (ARVI) in outpatient practice during the COVID-19 epidemic. Methodical recommendation. Version 2 from 16.04.2020. 18 p. (In Russ.) Available at https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf.

6. Evaluating the interaction risk of experimental COVID-19 therapies. Available at https://www.covid19-druginteractions.org/

7. Combined QT drugs lists (All TdP risk categories). Available at https://www.crediblemeds.org/index.php/tools/pdfdownload?f=cql_en.

8. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating, circumventing the QTc prolonging, and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc. 2020. doi:10.1016/j.mayocp.2020.03.024. [Epub ahead of print].

9. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. doi:10.1016/j.ijantimicag.2020.105949. [Epub ahead of print].

10. Driggin E, Madhavan MV, Bikdeli B. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems during the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol. 2020;pii:S0735-1097(20)34637-4. doi: 10.1016/j.jacc.2020.03.031. [Epub ahead of print].

11. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Heart Rhythm. 2020, pii: S1547- 5271(20)30347-7. doi:10.1016/j.hrthm.2020.04.016. [Epub ahead of print].

12. Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russ.) doi:10.15829/1560-4071-2020-3-3801.

13. World Health Organization. Adherence to long-term therapies: evidence for action. WHO Library Cataloguing-in-Publication Data, Geneva, WHO 2003. 211 р. Available at https://www.who.int/chp/knowledge/publications/adherence_report/en/.

14. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35. doi:10.1161/CIRCULATIONAHA.108.768986.

15. Martsevich SYu, Lukina YV, Kutishenko NP, et al. Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study). Rational Pharmacotherapy in Cardiology. 2019;15(6):864-72. (In Russ.) doi:10.20996/1819-6446-2019-15-6-864-72.